These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 27245499)

  • 1. The kynurenine pathway in schizophrenia and bipolar disorder.
    Erhardt S; Schwieler L; Imbeault S; Engberg G
    Neuropharmacology; 2017 Jan; 112(Pt B):297-306. PubMed ID: 27245499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum kynurenic acid is reduced in affective psychosis.
    Wurfel BE; Drevets WC; Bliss SA; McMillin JR; Suzuki H; Ford BN; Morris HM; Teague TK; Dantzer R; Savitz JB
    Transl Psychiatry; 2017 May; 7(5):e1115. PubMed ID: 28463241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder.
    Miller CL; Llenos IC; Dulay JR; Weis S
    Brain Res; 2006 Feb; 1073-1074():25-37. PubMed ID: 16448631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
    Fujigaki H; Yamamoto Y; Saito K
    Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine.
    Johansson AS; Owe-Larsson B; Asp L; Kocki T; Adler M; Hetta J; Gardner R; Lundkvist GB; Urbanska EM; Karlsson H
    J Psychiatr Res; 2013 Nov; 47(11):1815-23. PubMed ID: 24012176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
    Beggiato S; Notarangelo FM; Sathyasaikumar KV; Giorgini F; Schwarcz R
    J Psychopharmacol; 2018 Nov; 32(11):1223-1232. PubMed ID: 30354938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.
    Myint AM; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():304-13. PubMed ID: 24184687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia.
    Sathyasaikumar KV; Stachowski EK; Wonodi I; Roberts RC; Rassoulpour A; McMahon RP; Schwarcz R
    Schizophr Bull; 2011 Nov; 37(6):1147-56. PubMed ID: 21036897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder.
    Miller CL; Llenos IC; Cwik M; Walkup J; Weis S
    Neurochem Int; 2008 May; 52(6):1297-303. PubMed ID: 18328600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects.
    Müller N; Myint AM; Schwarz MJ
    Curr Pharm Des; 2011; 17(2):130-6. PubMed ID: 21361867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder.
    Sellgren CM; Kegel ME; Bergen SE; Ekman CJ; Olsson S; Larsson M; Vawter MP; Backlund L; Sullivan PF; Sklar P; Smoller JW; Magnusson PK; Hultman CM; Walther-Jallow L; Svensson CI; Lichtenstein P; Schalling M; Engberg G; Erhardt S; Landén M
    Mol Psychiatry; 2016 Oct; 21(10):1342-50. PubMed ID: 26666201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression.
    Lavebratt C; Olsson S; Backlund L; Frisén L; Sellgren C; Priebe L; Nikamo P; Träskman-Bendz L; Cichon S; Vawter MP; Osby U; Engberg G; Landén M; Erhardt S; Schalling M
    Mol Psychiatry; 2014 Mar; 19(3):334-41. PubMed ID: 23459468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive and Behavioral Changes in Kynurenine 3-Monooxygenase Knockout Mice: Relevance to Psychotic Disorders.
    Erhardt S; Pocivavsek A; Repici M; Liu XC; Imbeault S; Maddison DC; Thomas MAR; Smalley JL; Larsson MK; Muchowski PJ; Giorgini F; Schwarcz R
    Biol Psychiatry; 2017 Nov; 82(10):756-765. PubMed ID: 28187857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kynurenine pathway and white matter microstructure in bipolar disorder.
    Poletti S; Myint AM; Schüetze G; Bollettini I; Mazza E; Grillitsch D; Locatelli C; Schwarz M; Colombo C; Benedetti F
    Eur Arch Psychiatry Clin Neurosci; 2018 Mar; 268(2):157-168. PubMed ID: 27619930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases.
    Lovelace MD; Varney B; Sundaram G; Lennon MJ; Lim CK; Jacobs K; Guillemin GJ; Brew BJ
    Neuropharmacology; 2017 Jan; 112(Pt B):373-388. PubMed ID: 26995730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated kynurenine pathway metabolism during neurodevelopment: Implications for brain and behavior.
    Notarangelo FM; Pocivavsek A
    Neuropharmacology; 2017 Jan; 112(Pt B):275-285. PubMed ID: 26944732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linking phencyclidine intoxication to the tryptophan-kynurenine pathway: Therapeutic implications for schizophrenia.
    Fujigaki H; Mouri A; Yamamoto Y; Nabeshima T; Saito K
    Neurochem Int; 2019 May; 125():1-6. PubMed ID: 30731185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia.
    Tufvesson-Alm M; Schwieler L; Schwarcz R; Goiny M; Erhardt S; Engberg G
    Neuropharmacology; 2018 Aug; 138():130-139. PubMed ID: 29879409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The kynurenic acid hypothesis - a new look at etiopathogenesis and treatment of schizophrenia].
    Flis M; Szymona K; Morylowska-Topolska J; Urbańska A; Krukow P; Kandefer-Szerszeń M; Zdzisińska B; Urbańska EM; Karakuła-Juchnowicz H
    Pol Merkur Lekarski; 2016 Sep; 41(243):160-164. PubMed ID: 27755520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine.
    Koola MM
    Schizophr Res Cogn; 2016 Jun; 4():4-9. PubMed ID: 27069875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.